Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SONN
stocks logo

SONN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q3
FY2024Q4
28.50K
-22.66%
--
--
0.00
-100%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Sonnet BioTherapeutics Holdings, Inc. (SONN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -55.79%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-55.79%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Sonnet Biotherapeutics Holdings Inc (SONN.O) is -0.36, compared to its 5-year average forward P/E of -0.63. For a more detailed relative valuation and DCF analysis to assess Sonnet Biotherapeutics Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.63
Current PE
-0.36
Overvalued PE
-0.09
Undervalued PE
-1.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.07
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.12
Undervalued EV/EBITDA
-0.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
79.60
Current PS
0.00
Overvalued PS
160.20
Undervalued PS
-0.99
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SONN News & Events

Events Timeline

(ET)
2025-12-02
09:30:00
Sonnet BioTherapeutics Stockholders Approve Merger with Hyperliquid Strategies
select
2025-10-15 (ET)
2025-10-15
10:11:27
Sonnet BioTherapeutics and Spanios Partner for Non-Clinical Research on SON-1010
select
2025-08-11 (ET)
2025-08-11
09:19:44
Sonnet BioTherapeutics releases 'What This Means' investor segment
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-02Globenewswire
PinnedSonnet BioTherapeutics Secures Shareholder Approval for Merger with Hyperliquid Strategies
  • Shareholder Voting Results: Sonnet BioTherapeutics received approval at its special meeting for the proposed merger with Hyperliquid Strategies Inc and Rorschach I LLC, marking a significant step in the company's strategic transformation.
  • Technology Platform Advantage: Sonnet's FHAB technology utilizes fully human antibody fragments specifically targeting tumors and lymphatic tissues, enhancing the safety and efficacy of immune-modulating biologics, which is expected to strengthen its competitive position in the market.
  • Post-Merger Outlook: Upon completion of the merger, HSI's securities are expected to be listed on Nasdaq, providing Sonnet with broader access to capital markets and potential funding support to bolster its R&D and market expansion efforts.
  • Information Transparency: The company has mailed a detailed proxy statement/prospectus to shareholders, ensuring they are well-informed about the merger transaction, thereby enhancing corporate governance and transparency.
[object Object]
Preview
8.5
12-03Newsfilter
Hyperliquid Completes Merger with Sonnet, Stock to Trade on Nasdaq
  • Merger Completion: Hyperliquid Strategies Inc has completed its merger with Sonnet BioTherapeutics, with Sonnet shareholders' shares adjusted at a 5-for-1 ratio, marking the company's entry into the digital asset space and expected to enhance market competitiveness.
  • New Ticker Symbol: Following the merger, Hyperliquid's common stock will begin trading on Nasdaq under the ticker PURR on December 3, while Sonnet's stock will cease trading, reflecting the company's strategic positioning in the capital markets.
  • Leadership Team: The new company will be led by CEO David Schamis, with board members including Bob Diamond, ensuring a wealth of experience in financial services that will aid in driving future growth.
  • Market Opportunity: Hyperliquid's decentralized trading platform has become a market leader in perpetual futures and spot trading, processing billions in daily trading volume, providing investors with a direct opportunity to engage with this emerging network.
[object Object]
Preview
8.5
12-02Newsfilter
Sonnet BioTherapeutics Shareholders Approve Merger with Hyperliquid Strategies Inc.
  • Shareholder Vote Results: Sonnet BioTherapeutics' shareholders approved the business combination with Hyperliquid Strategies Inc and Rorschach I LLC at a special meeting, marking a significant step in the company's strategic transformation that is expected to enhance its competitiveness in the oncology biopharmaceutical sector.
  • Technology Platform Advantage: Sonnet's FHAB technology utilizes a fully human single-chain antibody fragment specifically targeting tumor and lymphatic tissues, improving the safety and efficacy of immune-modulating biologic drugs, thereby providing broader possibilities for future drug development.
  • Post-Merger Outlook: Upon completion of the merger, Sonnet is expected to list on Nasdaq, which will enhance its visibility in the capital markets and financing capabilities, accelerating its research and development processes and market expansion.
  • Transparency in Information: The company has mailed a detailed proxy statement/prospectus to shareholders, ensuring that all stakeholders are informed about the details and potential impacts of the merger transaction, reflecting a commitment to shareholder interests.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Sonnet Biotherapeutics Holdings Inc (SONN) stock price today?

The current price of SONN is 0 USD — it has decreased -146.03 % in the last trading day.

arrow icon

What is Sonnet Biotherapeutics Holdings Inc (SONN)'s business?

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

arrow icon

What is the price predicton of SONN Stock?

Wall Street analysts forecast SONN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SONN is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Sonnet Biotherapeutics Holdings Inc (SONN)'s revenue for the last quarter?

Sonnet Biotherapeutics Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Sonnet Biotherapeutics Holdings Inc (SONN)'s earnings per share (EPS) for the last quarter?

Sonnet Biotherapeutics Holdings Inc. EPS for the last quarter amounts to -0.95 USD, decreased -82.94 % YoY.

arrow icon

What changes have occurred in the market's expectations for Sonnet Biotherapeutics Holdings Inc (SONN)'s fundamentals?

The market is revising No Change the revenue expectations for Sonnet BioTherapeutics Holdings, Inc. (SONN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -55.79%.
arrow icon

How many employees does Sonnet Biotherapeutics Holdings Inc (SONN). have?

Sonnet Biotherapeutics Holdings Inc (SONN) has 13 emplpoyees as of December 05 2025.

arrow icon

What is Sonnet Biotherapeutics Holdings Inc (SONN) market cap?

Today SONN has the market capitalization of 2.95M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free